Ascorbate MRI Contrast Agent Formulation for Gadolinium Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current MRI contrast agents, particularly those based on gadolinium, pose risks such as nephrogenic systemic fibrosis and brain deposits, limiting their use in patients with renal insufficiency and raising concerns about long-term safety.
Innovation Solution
The use of ascorbate (Vitamin C) as a contrast agent for MRI, formulated in sterile aqueous solutions with sodium or meglumine, which can be administered parenterally to enhance MRI signal changes in tissues and fluids without the need for radioactivity or chemical labeling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If gadolinium-based contrast agents are used to enhance MRI signal, then diagnostic sensitivity and specificity are improved, but nephrogenic systemic fibrosis and brain deposits occur causing severe health risks
Solution Approach 1:
The patent extracts and eliminates the harmful gadolinium metal component from the contrast agent system, replacing it with safe, endogenous molecules (glucose, ascorbate, lactate) that can still enhance MRI signal through their natural paramagnetic properties or metabolic effects, thereby removing the source of nephrogenic systemic fibrosis and brain deposits while preserving diagnostic capability
Solution Approach 2:
The patent employs short-lived, rapidly clearing contrast agents such as glucose and ascorbate that are naturally metabolized or excreted by the body within minutes to hours, replacing the persistent gadolinium chelates that remain in the body and cause long-term accumulation in the brain and kidneys, thus eliminating chronic toxicity risks
2Measurement precision
If gadolinium-based contrast agents are used to improve MRI signal, then detection and characterization of diseases are enhanced, but patient safety is compromised especially in renal insufficiency
Solution Approach 1:
The patent introduces endogenous metabolic intermediates (glucose, ascorbate, lactate) as intermediary contrast agents that safely mediate between the MRI imaging system and the patient's biology, providing diagnostic information through their natural metabolic pathways without requiring toxic metal chelates, thus ensuring safety in patients with renal insufficiency
Solution Approach 2:
The patent changes the fundamental parameters of contrast agents from heavy metal-based (gadolinium) to light-element-based (carbon, hydrogen, oxygen in glucose/ascorbate/lactate), altering the mechanism of contrast enhancement from direct paramagnetic relaxation to metabolic trapping and pH-dependent relaxation, thereby improving safety while maintaining or enhancing diagnostic precision
3Measurement precision
If iron oxide-based nanoparticles are used as contrast agents, then MRI signal enhancement is achieved, but the agents are confined to blood pool and cleared by reticuloendothelial system limiting their utility
Solution Approach 1:
The patent changes the molecular size parameter from large iron oxide nanoparticles (confined by reticuloendothelial system) to small endogenous molecules (glucose, ascorbate, lactate) that can freely cross capillary membranes and distribute throughout interstitial and intracellular spaces, enabling versatile tissue penetration and metabolic-specific imaging while maintaining MRI signal enhancement capability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Ascorbate effectively enhances MRI signal changes in tissues and fluids, allowing for the detection and characterization of perfusion, metabolism, and oxidative stress, while being safe and biodegradable, thus addressing the limitations of existing contrast agents.
Implementation Method 1
Gd possesses strong 'paramagnetism' that results in a locally increased MRI signal on T1-weighted images
Data Source
AI summary
A sterile aqueous composition suitable for use as an MRI contrast agent includes 100 to 600 mM ascorbate; and 100-600 mM sodium, meglumine, or a combination thereof. The composition preferably has an osmolarity of 200 to 1400 mOsm/L.